Search

Search Constraints

You searched for: Author/Creator Tada, Fujimasa

Search Results

1. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

2. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

3. Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test. Issue 1 (15th September 2022)

4. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. (9th December 2022)

5. Pancreas stiffness in liver cirrhosis is an indicator of insulin secretion caused by portal hypertension and pancreatic congestion. Issue 7 (5th June 2021)

6. Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection. Issue 2 (20th November 2018)

7. Predictors of treatment efficacy and ALT non‐normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. Issue 9 (23rd May 2017)

8. Sex difference in the development of hepatocellular carcinoma after direct‐acting antiviral therapy in patients with HCV infection. Issue 12 (17th May 2020)

9. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data. Issue 2 (16th November 2022)

10. The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma. Issue 2 (6th November 2022)